flupentixol/melitracen / Generic mfg. - LARVOL DELTA

Predicting response to neuromodulators in refractory chronic cough: An interpretable machine learning approach. (PubMed, Ther Adv Respir Dis) - "BackgroundNeuromodulators (e.g., Gabapentin, Baclofen, and Flupentixol-melitracen) are widely prescribed for refractory chronic cough (RCC); however, heterogeneous treatment responses remain a significant challenge for optimal agent selection.ObjectivesThis study aimed to develop an interpretable machine learning (ML) model to predict individual patient responses to these therapies.DesignSingle-center retrospective observational study.MethodsThis retrospective cohort study included 730 patients with RCC treated with neuromodulators from 2016 to 2023. The free online clinical decision-support application was deployed.ConclusionWe developed and internally validated an interpretable ML model capable of predicting neuromodulator efficacy in RCC. The integration of SHAP clarifies feature attributions to support individualized, data-driven treatment selection."

Journal • Observational data • Retrospective data • Chronic Cough • Cough • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Pulmonary Disease • Respiratory Diseases

From Visceral Pain to Emotional Distress: Comparative Effectiveness of Antispasmodics and Antidepressants in Irritable Bowel Syndrome - Systematic Review and Network Meta-analysis. (PubMed, J Gastrointestin Liver Dis) - "Imipramine and alverine/simethicone were superior for reducing abdominal pain, whereas flupentixol-melitracen, peppermint oil, fluoxetine, and vortioxetine demonstrated the strongest anxiolytic effects. Effective options for depression included imipramine, venlafaxine, flupentixol-melitracen, desipramine, and vortioxetine. Notably, amitriptyline uniquely improved overall IBS severity scores, while otilonium bromide, venlafaxine, amitriptyline, and cumin sofouf provided the greatest benefits for QoL. These findings clarify comparative efficacy and may guide tailored pharmacotherapy strategies for IBS patients."

HEOR • Journal • Retrospective data • Review • CNS Disorders • Depression • Gastrointestinal Disorder • Mood Disorders • Pain • Psychiatry

Synergistic Modulation of Monoamine Circuitry: A Novel Non-Benzodiazepine Anxiolytic Strategy (CINP 2026) - "Aims & Objectives: This study proposes a novel pharmacological strategy combining very low-dose aripiprazole (1 mg) with low-dose escitalopram (2 mg). "Synergistic Modulation of Monoamine Circuitry" represents a contemporary evolution in anxiety management. By replacing the outdated components of therapies like Deanxit with a precision micro-dose of modern stabilizers and enhancers, this strategy offers a safer, non-addictive, and better-tolerated paradigm. This non-benzodiazepine approach warrants systematic clinical evaluation to replace legacy treatments and improve long-term outcomes for patients with anxiety and psychosomatic disorders."

Late-breaking abstract • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Psychosomatic Disorders • Schizophrenia • Sexual Disorders • DRD2

Combination of flupentixol and melitracen tablets and rTMS improves post-stroke depression through neurovegetative symptoms changes: a retrospective analysis. (PubMed, Front Neurol) - "There was significant difference in the amplitude and latency of P300 and NS after 2 weeks and 4 weeks treatment between the groups, while there was significant difference in the concentrations of 5-HT, NE, NPY, BDNF and the scores of NIHSS, HAMD17, BI, PSQI after 4 weeks treatment. Combination of flupentixol and melitracen tablets and rTMS could significantly improve the depressive symptoms of patients with PSD, NS was the symptom dimension most closely related to the therapeutic response. More importantly, the P300 parameter might provide an early and objective indicator of the neurophysiological changes associated with the treatment."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry • BDNF

Longitudinal Management of Post-traumatic Brain Injury Bipolar-Spectrum Disorder With Low-Dose Oral Glutamatergic Augmentation: Extended Follow-Up Revealing Induction, Overshoot, Stabilization, and Transition to PRN Maintenance. (PubMed, Cureus) - "After partial improvement on valproate, risperidone, and Deanxit, dextromethorphan 30 mg nightly and piracetam 600 mg nightly were added on 5 November 2025...Later medications included aripiprazole, paroxetine-controlled release, pregabalin, and low-dose quetiapine...The case is also only hypothesis-generating in relation to transcriptomic findings implicating bipolar-specific plasticity-related biology. Low-dose oral glutamatergic augmentation may warrant study as a closely monitored induction and consolidation strategy in post-TBI bipolar-spectrum illness, but prospective controlled trials are needed before broader recommendations can be made."

Journal • Bipolar Disorder • CNS Disorders • General Anxiety Disorder • Insomnia • Psychiatry • Sleep Disorder • Vascular Neurology

Effect of a Combined Antidepressant Drug Flupentixol-Melitracen on Glucose Level and Expression of Insulin-Like Peptide Genes DILP5 and DILP6 in Drosophila melanogaster. (PubMed, Biomed Res Int) - "The current study suggests that anxiolytics and antidepressant drugs might be associated with the insulin signaling pathway, which is crucial for growth, glucose regulation, and other fundamental metabolic processes. Further study is required to determine the expression pattern of all DILP and other genes that might affect glucose homeostasis."

Journal • CNS Disorders • Depression • Psychiatry

Transient Mood Elevation Without a Manic Switch: Goldenseal-Augmented Oral Glutamatergic Regimen in Bipolar Depression With Comorbid Obsessive-Compulsive Disorder (OCD). (PubMed, Cureus) - "In this report, we followed a 32-year-old man whose low mood and health-related ruminations lingered despite mood stabilisers (valproate, low-dose aripiprazole, pregabalin, and Deanxit). Hoping to copy some of ketamine's brain-circuit effects, he tried an over-the-counter mix of dextromethorphan, piracetam, and L-glutamine; the result was modest at best. Ten days after he added 600 mg of the herbal CYP2D6 inhibitor goldenseal, thought to slow the breakdown of dextromethorphan, he reported a clear lift in energy, mood, and work performance, with no signs of hypomania; the improvement faded when he stopped the herb and returned when he restarted it, and he had no side effects. Although this single experience cannot show cause and effect, it hints that short courses of a well-standardised botanical CYP2D6 inhibitor might prolong the benefit some patients get from oral dextromethorphan-based combinations, an idea that would need careful study, including drug-level..."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

RJYYQKLY-04: Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease (clinicaltrials.gov) - P=N/A | N=164 | Completed | Sponsor: RenJi Hospital | Active, not recruiting ➔ Completed | N=120 ➔ 164

Enrollment change • Trial completion • Gastroenterology • Gastroesophageal Reflux Disease

Assessment of SSD in Outpatients Using SSS-CN (clinicaltrials.gov) - P=N/A | N=1863 | Completed | Sponsor: RenJi Hospital | Recruiting ➔ Completed | N=700 ➔ 1863

Enrollment change • Trial completion • Psychosomatic Disorders

A Cross-Sectional Study on the Drug Use of Insomnia in a Chinese Medicine Hospital in Shenzhen. (PubMed, Psychiatry Clin Psychopharmacol) - "The 10 most commonly used drugs ranged from more to less were estazolam (29.99%), Zaoren anshen capsule (15.50%), oryzanol (14.82%), diazepam (14.51%), flupentixol and melitracen (14.30%), alprazolam (8.12%), zolpidem tartrate (5.29%), vitamin B6 (4.76%), sertraline (4.03%), and clonazepam (2.97%). The use of oryzanol and vitamin B6 was abused in Chinese medicine hospitals, and the use of Chinese medicine should be evaluated more rigorously. Nonbenzodiazepines should be promoted and more widely understood in the Chinese medicine hospital in Longgang, Shenzhen."

Journal • Observational data • CNS Disorders • Depression • Insomnia • Mental Retardation • Mood Disorders • Pain • Psychiatry • Sleep Disorder

Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial. (PubMed, EClinicalMedicine) - P4 | "Further trials using objective endpoints and longer follow-up in broader populations are needed to confirm efficacy and safety. The Project of Science and Technology Commission of Shanghai Municipality."

Clinical • Journal • Chronic Cough • CNS Disorders • Cough • Depression • Mood Disorders • Psychiatry • Pulmonary Disease • Renal Cell Carcinoma • Respiratory Diseases

RJYYQKLY-04: Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease (clinicaltrials.gov) - P=N/A | N=120 | Active, not recruiting | Sponsor: RenJi Hospital | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastroesophageal Reflux Disease

Therapeutic Efficacy of Flupentixol-Melitracen for Treatment of Aerophagia in Adults: A Single-Center Parallel Randomized Controlled Trial. (PubMed, JGH Open) - P4 | "Groups 1, 2, and 3 were treated with itopride hydrochloride, flupentixol-melitracen, and the combination of two medicines, respectively. The findings suggest that short-term treatment with flupentixol-melitracen, with or without a prokinetic benzamide derivative, is likely to improve symptoms of aerophagia in adults without significant adverse effects. Trial Registration: ClinicalTrials.gov identifier: ChiCTR-IPR-15006869."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain-bladder axis. (PubMed, Sci Rep) - P4 | "Patients in the control group (n = 62) received omeprazole for 4 weeks. Further studies are needed to confirm about brain-gut-bladder axis in EPS pathogenesis. Clinical Trials.gov (number: ChiCTR2400079677)."

Clinical • Journal • CNS Disorders • Depression • Dyspepsia • Musculoskeletal Pain • Pain • Psychiatry

Ebastine in combination with low-dose antidepressants for refractory irritable bowel syndrome: A randomized controlled trial. (PubMed, Technol Health Care) - "They were administered with ebastine (Group A) or ebastine combined with flupentixol and melitracen (Group B) for 4 weeks. After treatment, the serum levels of D-LAC and I-FABP were significantly lower in Group B than in Group A.ConclusionRefractory IBS patients showed certain psychological abnormalities. Ebastine combined with antidepressants exhibited more obvious benefits on QOL, sleep quality, and SSS, with significant improvements in psychological status and intestinal permeability in refractory IBS patients."

Journal • CNS Disorders • Depression • Gastrointestinal Disorder • Mood Disorders • Psychiatry

Effectiveness of simultaneous electroacupuncture stimulation on the tibial and ilioinguinal-iliohypogastric nerves in the treatment of refractory overactive bladder syndrome in women. (PubMed, Curr Urol) - "All patients in both groups had received anticholinergic muscarinic receptor antagonists (tolterodine/solifenacin), β3 receptor agonists, flupentixol/melitracen, and other basic treatment regimens with poor results. This therapy is safe, convenient, and free of significant adverse reactions, providing a new approach for the clinical treatment of refractory OAB in these patients. It significantly improves bladder symptoms and alleviates anxiety and depression, thereby markedly enhancing the patients' quality of life."

Journal • CNS Disorders • Depression • Mood Disorders • Overactive Bladder • Psychiatry • Urology

Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease (clinicaltrials.gov) - P=N/A | N=120 | Not yet recruiting | Sponsor: RenJi Hospital

New trial • Gastroenterology • Gastroesophageal Reflux Disease

Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia (clinicaltrials.gov) - P=N/A | N=200 | Not yet recruiting | Sponsor: RenJi Hospital

New trial • Dyspepsia

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

New P4 trial • Ophthalmology • Thyroid Eye Disease

Treatment indications for antidepressants prescribed in primary health care facilities in Beijing, China. (PubMed, Int Psychogeriatr) - "For these indications, the most frequently prescribed antidepressant was flupentixol/melitracen and sertraline.For 36.32 % of all antidepressant prescriptions,physicians prescribed a drug for an off-label indication,especially insomnia and pain.Physicians also prescribed antidepressants for several indications that were off-label for all antidepressants, including digestive system disorders and migraine. This study found compound antidepressants are widely prescribed and used off-label indications.There is a need for more evidence to evaluate the clinical outcomes associated with off-label antidepressant indications for older adults to optimise prescribing decisions at PHFs."

Journal • CNS Disorders • Depression • Gastroenterology • Gastrointestinal Disorder • Insomnia • Migraine • Mood Disorders • Pain • Psychiatry • Sleep Disorder

A Case of Pseudo Prolactin Elevation Caused by Medication. (PubMed, Clin Lab) - "Only effective communication between laboratory and clinical departments can make laboratory results more accurate and provide strong guarantees for clinical diagnosis and treatment."

Journal • Breast Cancer • Endocrine Cancer • Oncology • Pituitary Gland Carcinoma • Psychiatry • Solid Tumor

Antidepressant-induced Hyponatremia in Postmenopausal Females: A Case Series. (PubMed, J Midlife Health) - "The exact mechanism of hyponatremia with the use of antidepressants is not known; however, syndrome of inappropriate antidiuretic hormone secretion (SIADH) is presumed to be the reason. Here, we report two cases of antidepressant drug-induced hyponatremia in two postmenopausal females with no other risk factor for hyponatremia: one associated with mirtazapine and the other with flupentixol/melitracen."

Journal • Cardiovascular • Heart Failure

Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia (clinicaltrials.gov) - P=N/A | N=88 | Recruiting | Sponsor: Air Force Military Medical University, China

New trial • CNS Disorders • Dyspepsia

A multicenter retrospective study of antidepressant use in outpatient clinics in China pre- and post-COVID. (PubMed, Int J Clin Pharm) - "Over the past 5 years, both the number of patients and antidepressant prescriptions have shown upward trends, and the COVID-19 pandemic has impacted prescribing. Understanding the changes in antidepressant prescriptions can identify adherence to national guidelines."

Journal • Retrospective data • CNS Disorders • Depression • Infectious Disease • Novel Coronavirus Disease • Psychiatry

The efficacy and safety of NeuroWell antidepressant dietary supplement, Deanxit, and their combination in the treatment of mild-to-moderate depression: A randomized clinical trial. (PubMed, Genes Dis) - No abstract available

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry